Valuation: MedinCell

Market Cap 909M 1.03B 838M 783M 1.47B 97.66B 1.5B 10.05B 3.89B 48.14B 3.89B 3.8B 167B P/E 2026 *
-59.9x
P/E 2027 * 475x
Enterprise Value 893M 1.02B 823M 769M 1.44B 95.93B 1.47B 9.87B 3.82B 47.29B 3.82B 3.73B 164B EV / Sales 2026
32.7x
EV / Sales 2027 * 20x
Free-Float
70.46%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 09/01/2003
Director of Finance/CFO 52 01/09/2023
Chief Tech/Sci/R&D Officer 67 09/05/2022
Director TitleAgeSince
Director/Board Member 62 09/01/2003
Chairman - 13/03/2024
Director/Board Member - 25/05/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.02B
+0.93%+2.65%+42.33%+145.77% 996B
+1.61%+7.22%+60.81%+47.98% 580B
+3.51%+12.31%+31.15%+78.88% 415B
+0.99%+5.11%+29.26%+21.27% 326B
+1.09%+6.90%+37.22%+23.11% 284B
+1.34%+6.74%+32.63%+38.93% 280B
+1.32%+12.69%-27.48%-42.00% 210B
+0.40%+4.51%+25.85%+55.35% 190B
-1.05%+0.06%+16.91%+59.86% 155B
Average +1.01%+5.12%+27.63%+47.68% 381.86B
Weighted average by Cap. +1.31%+4.81%+35.33%+70.19%

Financials

2026 2027 *
Net sales 31.96M 36.38M 29.45M 27.53M 51.64M 3.43B 52.59M 353M 137M 1.69B 137M 134M 5.88B 44.78M 50.97M 41.25M 38.57M 72.35M 4.81B 73.67M 495M 192M 2.37B 191M 187M 8.24B
Net income -13.98M -15.92M -12.88M -12.04M -22.59M -1.5B -23M -155M -59.86M -740M -59.77M -58.46M -2.57B 786K 894K 724K 677K 1.27M 84.4M 1.29M 8.69M 3.36M 41.61M 3.36M 3.29M 145M
Net Debt -16.07M -18.29M -14.8M -13.84M -25.96M -1.73B -26.44M -178M -68.79M -851M -68.69M -67.18M -2.96B -14.87M -16.92M -13.7M -12.81M -24.02M -1.6B -24.46M -164M -63.66M -787M -63.56M -62.16M -2.74B
Logo MedinCell
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2025, the company had a portfolio of 2 products in phase III clinical development and 3 products in preclinical development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
25.32EUR
Average target price
34.51EUR
Spread / Average Target
+36.30%

Quarterly revenue - Rate of surprise